Recent developments in the chemistry and in the biological applications of amidoximes

Current Pharmaceutical Design

Volumn 14, Issue 10, 2008, Pages 1001-1047

  Fylaktakidou, K C ^a   Hadjipavlou Litina, D J ^b   Litinas, K E ^b   Varella, E A ^b   Nicolaides, D N ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Amidines; Amidoximes; Biological activities; NO donors; Prodrugs

Indexed keywords

1 METHYLIMIDAZOLE 5 AMIDOXIME; 1,2,4 OXADIAZOLE DERIVATIVE; 2 ETHOXY 2 NAPHTHYLACETAMIDOXIME; 2 ETHOXY 2 PHENYLACETAMIDOXIME; 2 HYDROXYACETAMIDOXIME; 4 CHLOROBENZAMIDOXIME; [2 (2 PHENYLTHIO)PHENYL]ACETAMIDOXIME; ACETAMIDOXIME; ACETYLSALICYLIC ACID; AMIDINE; AMIDOXIME DERIVATIVE; BENZAMIDINE; BENZAMIDOXIME; BENZYLAMIDOXIME; BISAMIDOXIME; DIMINAZENE ACETURATE; FLUNITRAZEPAM; FORMAMIDE OXIME; GLYCERYL TRINITRATE; IMIPRAMINE; INDAN DERIVATIVE; LAMIFIBAN; MELAGATRAN; OXIME; OXIME DERIVATIVE; PENTAMIDINE; PIRACETAM; SIBRAFIBAN; UNINDEXED DRUG; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; AFRICAN TRYPANOSOMIASIS; AMNESIA; ANTHELMINTIC ACTIVITY; ANTIARRHYTHMIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTICOAGULATION; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTERY THROMBOSIS; BACTERIOSTASIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG RETENTION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSFORMATION; FIBROSARCOMA; FUNGICIDAL ACTIVITY; HERBICIDAL ACTIVITY; HUMAN; HYPERTENSION; IC 50; INSECTICIDAL ACTIVITY; INTRAOCULAR HYPERTENSION; LEUKEMIA; LIVER CELL CARCINOMA; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PTOSIS; REVIEW; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; TRANQUILIZING ACTIVITY;

ANTI-ALLERGIC AGENTS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; NITRIC OXIDE DONORS; OXIMES; PESTICIDES; PLATELET AGGREGATION INHIBITORS; PRODRUGS;

EID: 44449086440     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784139675     Document Type: Review

References (360)

1. Nicolaides DN, Varella EA. In: Patai S Ed., Interscience, the chemistry of acid derivatives; the chemistry of amidoximes. New York, 1992; 2(Suppl. B, Pt 2): 875-966.
2. Eloy F, Lenaers R. The chemistry of amidoximes and related compounds. Chem Rev 1962; 62:155-83.
3. Zinner G, Perner M, Grünefeld J, Schecker HG. Untersuchungen in der reihe der N1-hydroxyamidine: Synthesen und umsetzungen mit isocyanaten und 1,1′-carbonyl-diimidazol. Arch Pharm 1986; 319: 1073-9.
4. Hussein AC. Reaction of amidoximes with a-chloroalkanoic acid chlorides: novel synthesis of 1,2,4-oxadiazin-5-ones. Heterocycles 1987; 26: 163-73.
5. Chakravarty S, Deb MK, Mishra RK. Hydroxyamidines as new extracting reagents for spectrophotometric determination of cadmium with 4-(2-pyridylazo)naphthol in industrial effluents, coal, and fly ash. J AOAC Int 1993; 76(3): 604-8.
6. Deb MK, Mishra N, Patel KS, Mishra RK. Sensitive spectrophotometric determination of osmium with pyrocatechol and hydroxyamidine. Analyst 1991; 116: 323-5.
7. Briggs LK, Cambie RC, Dean C, Rutledge PS. Some hydroxy-amidines and amidoximes. Aust J Chem 1976; 29: 357-66.
8. Hébert N, Hannah AL, Sutton SC. Synthesis of oxadiazoles on solid support. Tetrahedron Lett 1999; 40: 8547-50.
9. Rice KD, Nuss JM. An improved synthesis of 1,2,4-oxadiazoles on solid support. Bioorg Med Chem Lett 2001; 11: 753-5.
10. Anbazhagan M, Stephens CE, Boykin DW. Palladium-catalyzed N-arylation of O-methylamidoximes. Tetrahedron Lett 2002; 43: 4221-4.
11. Anbazhagan M, Boykin DW, Stephens CE. Regioselective cleavage of O-benzyl-N-arylamidoximes: Synthesis of N-aryl amidines and amidoximes. Tetrahedron Lett 2002; 43: 9089-92.
12. Kurz T, Widyan K. Efficient conversion of o-substituted 3-hydroxy-4-imino-oxazolidin-2-ones into O-substituted α-hydroxyamidoximes. Org Lett 2004; 6: 4403-5.
13. Borg S, Estenne-Bouhtou G, Luthman K, Csoregh I, Hesselink W, Haeksell U. Synthesis of 1,2,4-oxadiazole-, 1,3,4-oxadiazole-, and 1,2,4-triazole-derived dipeptidomimetics. J Org Chem 1995; 60: 3112-20 and references therein.
14. Watjcn F, Baker R, Engelstoff M, Herbert R, Macleod A, Knight A, et al. Novel benzodiazepine receptor partial agonists: oxadiazolylimidazobenzodiazepines. J Med Chem 1999; 32: 2282-91.
15. Showell GA, Gibbons TL, Kneen CO, MacLeod AM, Merchant K, Saunders J, et al. Tetrahydropyridyloxadiazoles: Semirigid muscarinic ligands. J Med Chem 1991; 34: 1086-94.
16. Orlek BS, Blaney FE, Brown F, Clark MSG, Hadley MS, Hatcher J, et al. Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. J Med Chem 1991; 34: 2726-35.
17. Diana GD, Volkots DL, Hitz TJ, Bailey TR, Long MA, Vescio N, et al. Oxadiazoles as ester bioisosteric replacements in compounds related to disoxaril. antirhinovirus activity. J Med Chem 1994; 37: 2421-36.
18. Oussaid. B, Moeini L, Martin B, Villemin D, Garrigues B. Improved synthesis of oxadiazoles under microwave irradiation. Synth Commun 1995; 25: 1451-9.
19. Young JR, DeVita RJ. Novel synthesis of oxadiazoles via palladium catalysis. Tetrahedron Lett 1998; 39: 3931-4.
20. Sams CK, Lau J. Solid-phase synthesis of 1,2,4-oxadiazoles. Tetrahedron Lett 1999; 40: 9359-62.
21. Liang GB, Qian X. Oxadiazole synthesis on solid supports. Bioorg Med Chem Lett 1999; 9: 2101-4.
22. Barrett AGM, Cramp SM, Roberts RS, Zécri FJ. Chromatography-free synthesis of 1,2,4-oxadiazoles using ROMPGEL-supported acylating reagents. Comb Chem High Throughput Screen 2000; 3: 131-8.
23. Wang Y, Miller RI, Sauer DR, Djuric SW. Rapid and efficient synthesis of 1,2,4-oxadiazoles utilizing polymer-supported reagents under microwave heating. Org Lett 2005; 7: 925-8.
24. Du W, Hagmann WK, Hale JJ. A 'one-pot' synthesis of α-1,2,4-oxadiazollo esters from malonic diesters and amidoximes under solvent-free conditions. Tetrahedron Lett 2006; 47: 4271-4.
25. Judkins BD, Allen DG, Cook TA, Evans B. Sardhawala TE. A versatile synthesis of amidines from nitriles via amidoximes. Synth Commun 1996; 26: 4351-67.
26. Zierke T, Mack H. Method for producing amidines. WO 0061574, 2000; Chem Abstr 2000; 133, P282087.
27. Heiner J, Seuring B, Herchen J, Kulitzscher B, Wunner J, Steueber W, et al. Efficient kg-scale synthesis of thrombin inhibitor CRC 220. Tetrahedron 1995; 51: 12047-68.
28. Broughton BJ, Chaplen P, Knoweles P, Lunt E, marshall MS, Pain DL, et al. Antiallergic activity of 2-phenyl-8-azapurin-6-ones. J Med Chem 1975; 19: 1117-22.
29. Akazome M, Kondo T, Watanabe Y. Ruthenium complex-catalyzed sencitive deoxygenation of amidoximes to amidines and its application to the facile synthesis of pyrimidines. J Mol Catal 1993; 80: 383-93.
30. Cesar J, Nadrah K, Dolenc MS. Solid-phase synthesis of amidines. by the reduction of amidoximes. Tetrahedron Lett 2004; 45: 7445-9.
31. Anbazhagan M, Boykin DW, Stephens CE. Direct conversion of amidoximes to amidines via transfer hydrogenation. Synthesis 2003; 2467-9.
32. Vadon-Le Goff S. Boucher JI, Mansuy DC Oxidation of arylamidoximes by various chemical and biomimetic systems: Comparison with their oxidations by hemeproteins. R Acad Sci Paris Série IIe Chimie/ Chemistry 2000; 3: 785-92.
33. Jousserandot A, Boucher JL, Henry Y, Niklaus B, Clement B, Mansuy D. Microsomal cytochrome P450 dependent oxidation of N-hydroxyguanidines, amidoximes, and ketoximes: Mechanism of the oxidative cleavage of their C=N(OH) bond with formation of nitrogen oxides. Biochemistry 1998; 37: 17179-91.
34. 2-dependent activity of nitric oxide synthasc. Bioorg Med Chem Lett 2000; 10: 1775-7.
35. Öcal N, Erden I. Oxidative cleavage of the C=N bond during singlet oxygenations of amidoximes. Tetrahedron Lett 2001; 42: 4765-7.
36. Koikov LN, Alexeeva NV, Lisitza EA, Krichevsky ES, Grigoryev NB, Danilov AV, et al. Oximes, amidoximes and hydroxamic acids as nitric oxide donors. Mendeleev Commun 1998; 165-8.
37. Ignarro L, Murad F. Nitric Oxide: Biochemistry, molecular biology, and therapeutic implications. Academic Press: San Diego, 1995.
38. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric oxide from L-arginine: A pathway for the regulation of cell function and communication. Biochem Pharm. 1989; 38: 1709-15.
39. Marietta MA. Mammallian synthesis of nitrite, nitrate, nitric oxide, and N-nitrosating agents. Chem Res Toxicol 1988; 1: 249-57.
40. Moncada S, Palmer R, Higgs EA. Nitric-oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991: 43: 109-42.
41. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995; 9: 1319-30.
42. Crow JP, Beckman JS. The importance of superoxide in nitric oxide-dependent toxicity: Evidence for peroxynitrite-mediated injury. Adv Exp Med Biol 1996; 387: 147-61.
43. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the-bad, and ugly. Am J Physiol 1996; 271: C1424-37.
44. Brunelli L, Crow J, Beckman J. The comparative toxicity of nitric oxide and peroxynitrite to Escherichia coli. Arch Biochem Biophys 1995; 316: 327-34.
45. Szabó C. The role of peroxynitrite in the pathophysiology of shock, inflammation and ischemia-reperfusion injury. Shock 1996; 6: 79-88.
46. Southan GJ, Salzman AL, Szabó C. Hydroxyquanidines inhibit peroxynitrite-induced oxidation. Free Rad Biol Med 1998; 25: 914-25
47. Wang PG, Xian M, Tang X, Wu X, Wen Z, Cai T, et al. Nitric oxide donors: Chemical activities and biological applications. Chem Rev 2002; 102: 1091-134.
48. Förstermann U, Scshmidt HHHW, Pollock JS, Sheng H, Mitchell JA, Warmer TD, et al. Isoforms of nitric oxide synthase characterization and purification from different cell types. Biochem Pharmacol 1991; 42: 1849-57.
49. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: Structure, function and inhibition. Biochem J 2001; 357: 593-615.
50. Pfeiffer S, Mayer B, Hemmens B. Nitric oxide: Chemical puzzles posed by a biological messenger. Angew Chem Int Ed 1999; 38: 1714-31.
51. Stuehr DJ, Kwon NS, Nathan CF, Griffith OW, Feldman PL, Wiseman J. N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine. J Biol Chem 1991; 266: 6259-63.
52. Marietta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993; 268: 12231-34.
53. Feldman PL, Griffith OW, Stuehr DJ. The surprising life of nitric oxide. Chem Eng News 1993; 26-38.
54. Klatt P, Schmidt K, Uray G, Mayer B. Multiple catalytic functions of brain nitric oxide synthase: Biochemical characterization, cofactor-requirement, and the role of Nω-hydroxy-L-arginine as an intermediate. J Biol Chem 1993; 268: 14781-7.
55. Mansuy D, Boucher JL, Clement B. On the mechanism of nitric oxide formation upon oxidative cleavage of C=N(OH) bonds by NO-synthases and cytochromes P450. Biochimie 1995; 77: 661-7.
56. 2 to nitric oxide and citruline. Biochem Biophys Res Commun 1992; 187: 880-6.
57. Boucher JL, Genet A, Vadom S, Delaforge M, Mansuy D. Formation of nitrogen-oxides and citrulline upon oxidation of N-omega-hydroxy-L-arginine by hemeproteins. Biochem Biophys Res Commun 1992; 184: 1158-64.
58. White KA, Marietta MA. Nitric oxide synthase is a cytochrome P450 type hemoprotein. Biochemistry 1992; 31: 6627-31.
59. Stuehr DJ, Saito MI. Spectral characterization of brain and macrophage nitric oxide synthases. J Biol Chem 1992; 267: 20547-50.
60. McMillan K, Bredt DS, Hirsh DJ, Snyder SH, Clark JE, Masters BSS. Cloned, expessed rat cerebellar nitric oxide synthase contains stoichiometric amounds of heme which binds carbon monoxide. Proc Natl Acad Sci USA 1992; 89: 11141-5.
61. Mansuy D, Boucher JL. Alternative nitric oxide-producing substrates for NO synthesis. Free Rad Biol Med 2004; 37: 1105-21.
62. Renaud JP, Boucher JL, Vadon S, Delaforge M, Mansuy D. Particular ability of liver P450s3A to catalyze the oxidation of Nω hydroxyarginine to citrulline and nitrogen oxides and occurrence in NO synthases of a sequence very similar to the home binding sequence in P450s. Biochem Biophys Res Commun 1993; 192: 53-60.
63. Clement B. The oxidation of benzamidines in vitro. Xenobiotica 1983; 13: 467-73.
64. Clement B, Jung F. N-hydroxylation of antiprotozoal drug pentamidine catalyzed by rabbit liver cytochrome P450 2C3 or human liver microsomes, microsomal retroreduction, and further oxidative transformation of the formed amidoximes. Drug Metab Disp 1994; 22: 486-97.
65. Clement B, Schultze-Mosgau MH, Wohlers H. Cytochrome P450-dependent N-hydroxylation of a guanidine (debrisoquine), microsomal catolyzed reduction and further oxidation of the N-hydroxyguanidine metabolite to the urea derivative. Biochem Pharmacol 1993; 46: 2249-67.
66. Clement B. Oxidation and reduction of nitrogen via CYP450: Importance of the reduction of genotoxic N-hydroxylated functional groups. Drug metabolism: Towards the new millenium; IOS Press: Amsterdam, 1998; 59-71.
67. Clement B, Christiansen K, Girreser U. Phase 2 metabolites of N-hydroxylated amidines (amidoximes): Synthesis, in vitro formation by pig hepatocytes, and mutagenicity testing. Chem Res Toxicol 2001; 14: 319-26.
68. Fröhlich AK, Girreser U, Clement B. Metabolism of benzamidoxime (N-hydroxyamidine) in human hepatocytes and role of UDP-glucuronosyltransferases. Xenobiotica 2005; 35: 17-25.
69. Clement B. Biotransformation stark basischer funktioneller gruppen durch stickstoffoxidation, hochschul sammlung naturwissenschaft, chemie and pharmazie, Bd. 3 ISBN 3 8 107 2212 X, HochschulVerlag, Freiburg, 1986.
70. Clement B, Immel M, Pfunder H, Schmidt S, Zimmerman M. In: Hlavica P, Damani LA Ed, N-oxidation of drugs. Chapman and Hall, London, 1991; pp. 185-205.
71. Clement B, Immel M, Raether W. Metabolic N-hydroxylation of diminazene in vitro. Arzneimittel-Forschung/Drug Res 1992; 42: 1497-504.
72. Berger BJ, Lombardly RJ, Marbury GD, Bell CA, Dykstra CC, Bell JE, et al. Metabolic N-hydroxylation of pentamidine in vitro. Antimicrob Agents Chemother 1990; 34: 1678-84.
73. Clement B, Immel M, Terlinden R, Winger FJ. Reduction of amidoxime derivatives to pentamidine in vivo. Arch Pharm 1992; 325: 61-2
74. Berger BJ, Naiman NA, Hall JE, Peggins J, Brewer TG, Tidwell RR. Primary and secondary metabolism of pentamidine by rats. Antimicrob Agents Chemother 1992; 36: 1825-31
75. Clement B, Jung F. N-hydroxylation and N-Dealkylation by P450 of N-methylbenzamidine: N-oxygenation and N-oxidative dealkylation of one functional group. Xenobiotica 1995; 25: 443-55.
76. ω-hydroxy-L-arginine and other compounds bearing a C=NOH function in the rat aorta. J Pharm Exp Ther 2002; 303: 823-30.
77. Renodon-Cornière A, Dijols S, Perollier C, Lefevre-Groboillot D, Boucher JL, Attias R, et al. N-Aryl N'-hydroxyguanidines, a new class of NO-donors after selective oxidation by nitric oxide synthases: Structure-activity relationships. J Med Chem 2002; 45: 944-54.
78. Andronik-Lion V, Boucher JL, Delaforge M, Henry Y, Mansuy D. Formation of nitric oxide by cytochrome P450 catalyzed oxidation of aromatic amidoximes. Biochem Biophys Res Commun 1992; 185: 452-8.
79. Ortiz de Montellano PR, Reich N. O. In: Ortiz de Montellano PR Ed, Cytochrome P-450, structure, mechanism and biochemistry; Plenum Press, New York, 1986; pp. 273-314.
80. Jousserandot A, Boucher JL, Desseaux C, Delaforge M, Mansuy D. Formation of nitrogen oxides including NO from oxidative cleavage of C=N(OH) bonds: A general cytochrome P450-dependent reaction. Bioorg Med Chem Lett 1995; 5: 423-6.
81. Sennequier N, Boucher JL, Battioni P, Mansuy D. Superoxide anion efficiently performs the oxidative cleavage of C=NOH bonds of amidoximes and N-hydroxyguanidines with formation of nitrogen oxides. Tetrahedron Lett 1995; 34: 6059-62.
82. Ortiz de Montellano PR. In: Ortiz de Montellano PR Ed, Cytochrome P450: structure, mechanism, and biochemistry 2nd ed., Plenum Press, New York, 1995; pp. 245-304.
83. Clement B. Reduction of N-hydroxylated compounds: Amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev 2002; 34: 565-79.
84. G-hydroxy-L-arginine causes nitrite production in vascular smooth muscle cells in the absence of nitric oxide synthase activity. FEBS Lett 1994; 341: 203-7.
85. Jia Y, Zacour M, Tolloczko B, Martin JG. Nitric oxide synthesis by tracheal smooth muscle cells by a nitric oxide synthase-independent pathway. Am J Physiol 1998; 275: L895-901.
86. ω-hydroxyarginine. J Med Chem 2001; 44: 3199-202.
87. Caro AA, Cederbaum AI, Stoyanovsky DA. Oxidation of the ketoxime acetoxime to nitric oxide by oxygen radical generating systems. Nitric Oxide 2001; 5: 413-24.
88. Lefevre-Groboillot D, Dijols S, Boucher JL, Mahy JP, Ricoux R, Desbois A, et al. N-hydroxyguanidines as new heme ligands: UV-visible, EPR, and resonance Raman studies of the interaction of various compounds bearing a C=NOH function with microperoxidase-8. Biochemistry 2001; 40: 9909-17.
89. Clement B, Schmezer P, Weber H, Schlehofer JR, Schmidt S, Pool BL. Genotoxic activities of benzamidine and its N-hydroxylated metabolite benzamidoxime in S. typhimurium and in mammalian cells. J Cancer Res Clin Oncol 1988; 114: 363-8.
90. Clement B, Demesmaeker M, Linne S. Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: Characterization of the two reactions and genotoxic potential of guanabenz. Chem Res Toxicol 1996; 9: 682-8
91. Clement B, Schmidt S, Zimmerman M. Enzymatic reduction of benzamidoxime to benzamidine. Arch Pharm 1988; 321: 955-6.
92. Hautpmann J, Paintz M, Kaiser B, Richter M. Reduction of benzamidoxime derivative to the corresponding benzamidine in vivo and in vitro. Pharmazie 1988; 43: 559-60.
93. Clement B, Zimmerman M, Schmidt S. Biotransformation des benzamidins und des benzamidoxims durch mikrosomale enzyme von kaninchen. Arch Pharm 1989; 322: 431-6.
94. Clement B, Immel M, Schmidt S, Steinmann U. Biotransformations of benzamidine and benzamidoxime in vivo. Arch Pharm 1993; 326: 807-12.
95. 2-insensitive NADH-benzamidoxime reductase. J Biol Chem 1997; 272: 19615-20.
96. Clement B, Schultze-Mosgau MH, Richter M, Besch A. Cytochrome P450 dependent N-hydroxylation of an aminoguanidine (amidinohydrazone) and microsomal retroreduction of the N-hydroxylated product. Xenobiotica, 1994; 24: 671-88.
97. Clement B, Demesmaeker M. Formation of guanoxabenz from guanabenz in human liver: A new metabolic marker for CYP1A2. Drug Metab Dispos 1997; 25: 1266-71.
98. Clement B, Lopian K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Disp 2003; 31: 645-51.
99. Gustafsson D, Nyström JF. Carlsson S, Bredberg U, Eriksson U, Gyzander E, et al. The direct thrombin inhibitor melagatran and its oral prodrug H376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81.
100. Gustafsson D, Nyström JE, Carlsson S, Bredberg U, Elg M, Gyzander E, et al. Pharmacodynamic properties of H376/95, a prodrug of the direct thrombin inhibitor melagatran, intended for oral use. Blood 1999; 94(Suppl 1, Pt 1): 102.
101. 325-hydroxylase. Biochem Biophys Res Commun 1997; 241: 491-7.
102. 5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharm Exp Ther 2004; 311: 1171-8.
103. Heberling S, Girreser U, Wolf s, Clement B. Oxygen-insensitive enzymatic reduction of oximes to imines. Biochem Pharmacol 2006; 71: 354-65.
104. 5 reductase. Drug Metab Dispos 2005; 33: 1886-93.
105. Clement U, Mau S, Deters S, Havemeyer A. Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylation prodrugs benzamidoxime, guanobenz, and Ro 48-3656. Drug Metab Dispos 2005; 33: 1740-7.
106. Cribb AE, Spielberg SP, Griffin GP. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995; 23: 406-14.
107. Lin J, Berkman CE, Cashman JR. N-oxygenation of primary amines and hydroxylamines and retroreduction of hydroxylamines by adult human liver microsomes and adult human flavin-containing monooxygenase 3. Chem Res Toxicol 1996; 9:1183-93.
108. Trepanier LA, Miller JL. NADH-dependent reduction of sulphamethoxazole hydroxylamine in dog and human liver microsomes. Xenobiotica 2000; 30: 1111-21.
109. Andersson S, Hofmann Y, Nordling A, Li XQ, Nivelius S, Andersson TB, et al. Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime. Drug Metab Dispos 2005; 33: 570-8.
110. Johansson I, Thelin A, Hofmann Y, Andersson S, Nordling Å, Li QX, et al. Identification of stearoyl CoA desaturase as the enzyme responsible for the reduction of ximelagatran/N-hydroxymelagatran and benzamidoxime in adipocytes. Drug Metab Rev 2005; 37(Suppl. 1): 48-9.
111. 2 generation, and ferric reduction. Arch Biochem Biophys 1996; 331: 69-78.
112. Sikto GR, Ramijit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoangulant peptide-comparison to hirudin and heparin in a canine model of acute coronary-artery thrombosis. Circulation 1992; 85: 805-15.
113. Morishima Y, Tanabe K, Terada Y, Hara T, Kunitada S. Anti-thrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: Comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997; 78: 1366-71.
114. Heran C, Morgan S, Kasiewski C, Bostwick J, Bentley R, Klein S, et al. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis. Eur J Pharmacol 2000; 389: 201-7.
115. Sato K, Kawasaki T, Taniuchi Y, Hirayama F, Koshio H, Matsumoto Y. YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of blooding time. Eur J Pharmacol 1997; 339: 141-6.
116. Kawasaki T, Sato K, Hirayama F, Koshio H, Taniuchi Y, Matsumoto Y. Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis. Thromb Haemost 1998; 79: 859-64.
117. Sato K, Kawasaki T, Hisamichi N, Taniuchi Y, Hirayama F, Koshio H, et al. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. J Pharmacol 1998; 123: 92-6.
118. Koshio H, Hirayama F, Ishihara T, Kaizawa H, Shigenaga T, Taniuchi Y, et al. Orally active factor Xa inhibitor: Synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives. Bioorg Med Chem 2004; 12: 5415-26.
119. Song Y, Clizbe L, Bhakta C, Teng W, Wong P, Huang B, et al. Design and synthesis of factor xa inhibitors and their prodrugs. Bioorg Med Chem Lett 2003; 13: 297-300.
120. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26: 76-82.
121. Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemostasis 1997; 78: 1142-9.
122. Suleymanov OD, Szalony JA, Salyers AK, Lachance RM, Parlow JJ, South MS, et al. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/ factor VIIa inhibitor: Comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmool Exp Ther 2003; 306: 1115-21.
123. Olivero AG, Eigenbrot C, Goldsmith R, Robarge K, Artis DR, Flygare J, et al. A Selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. J Biol Chem 2005; 280: 9160-9.
124. Riggs JR, Kolesnikov A, Hendrix J, Young WB, Shrader WD, Vijaykumar D, et al. Factor VIIa inhibitors: A prodrug strategy to improve oral bioavailability. Bioorg Med Chem Lett 2006; 16: 2224-8.
125. Poncz M, Eisman R, Heidenreich R, Silver SM, Surrey S, Schwartz E, et al. Structure of the platelet membrane glycoprotein IIb. Homology to the alpha subunits of the vitronectin and fibronectin membrane receptors. J Biol Chem 1987; 262: 8476-82.
126. Phillips DR, Fitzgerald LA, Charo IF, Parise LV. The platelet membrane glycoprotein IIb/IIIa complex. Structure, function, and relationship to adhesive protein receptors in nucleated cells. Ann N Y Acad Sci 1987; 509: 177-87.
127. Alig L, Edenhofer A, Hadváry P, Hürzeler M, Knopp D, Müller M, et al. Low Molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992; 35: 4393-407.
128. Cook NS, Bruttger O, Pally C, Hagenbach A. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea pigs and dogs: Evidence that Ro 43-8857 is orally active. Thromb Haemostasis 1993; 70: 838-47.
129. Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadváry P, et al. Orally active fibrinogen receptor antagonists. 2. amidoximes as prodrugs of amidines. J Med Chem 1996; 39: 3139-47.
130. Refino CJ, Modi NB, Bullens S, Pater C, Lipari MT, Robarge K, et al. Pharmacogenetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. Thromb Haemost 1998; 79: 169-76.
131. Kitamura S, Fukushi H, Miyawaki T, Kawamura M, Terashita ZI, Naka T. Orally active GPIIb/IIIa antagonists: Synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4-[2S)-2-(4-amidinobenzoylamino)-3-(4-methoxyphenyl) propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic acid. Chem Pharm Bull 2001; 49: 268-77.
132. Rehse K, Bade S, Harsdorf A, Clement B. New NO-donors with antithrombic and vasodilating activities, part 17. Arylazoamidoximes and 3-arylazo-1,2,4-oxadiazol-5-ones. Arch Pharm Pharm Med Chem 1997; 392-8.
133. Rehse K, Brehme F. New NO-donors with antithrombic and vasodilating activities, part 26. amidoximes and their prodrugs. Arch Pharm Pharm Med Chem 1998; 375-9.
134. Topliss JG. Utilization of operational schemes for analog synthesis in drug design. J Med Chem 1972; 15: 1006-11.
135. Duchstein HJ, Riederer S. Vorstellungen zur freisetzung von stickstoffmonoxid aus NO-pharmaka. modellreaktionen in gegenwart von licht und übergangsmetallkomplexen, 1. Mitt Arch Pharm (Weinheim) 1995; 328: 317-24.
136. Monge A, Palop J, Urbasos I, Fernandezalverez E. New quinoxaline and pyrimido[4,5-b]quinoxaline derivatives-potential antihypertensive and blood-platelet antiaggregating agents. J Heterocycl Chem 1989; 26: 1623-6.
137. Lukevics E, Barbarella G, Arsenyan P, Shestakova I, Belyakov S, Popelis J, et al. Synthesis, structure and cytotoxicity of trimethylsilyl oligothienylcarbaldehydes and their derivatives. J Organometallic Chem 2001; 636: 26-30.
138. Ciofalo M, Petruso S, Schillaci D. Quantitative assay of photoinduced antibiotic activities of naturally-occurring 2,2′:5′,2″-terthiophenes. Planta Med 1996; 62: 374-5.
139. Ahmad VU, Alam N. New antifungal bithienylacetylenes from Blumea obliqua. J Nat Prod 1995; 58: 1426-9.
140. Hudson JB, Marles RJ, Soucy-Breau C, Harris L, Amason JT. Photoactive terthiophenes-the influence of serum on anti-HIV (Human-Immunodeficiency-virus) activities. Photochem Photobiol 1994; 60: 591-3.
141. Perich MJ, Wells C, Bertsch W, Tredway KE. Isolation of the insecticidal components of tagetes minuta (compositae) against mosquito larvae and adults. J Am Mosq Control Assoc 1995; 11: 307-10.
142. Guillet G, Harmatha J, Waddell TG, Philogene BJ, Arnason JT. Synergistic insecticidal mode of action between sesquiterpene lactones and a phototoxin, alpha-terthienyl. Photochem Photobiol 2000; 71: 111-5.
143. Lukevics E, Erchak NP, Demicheva LE, Verovskii VN, Augustane I. Synthesis and cytotoxicity of furfurol derivatives. Khim-Farm Zh 1992; 26: 45-8.
144. Lukevics E, Erchak NP, Castro I, Zidermane AA, Dauvarte A. Nitrogen-containing organosilicon compounds. CXIX. Synthesis and biological activity of 5-trimethylsilylfuran derivatives containing azomethine and vinyl groups in the ring. Zh Izv Akad Nauk Latv SSR Ser Khim 1983; 735-8.
145. Becquet F, Courtois Y, Goureau O. Nitric oxide in the eye: Multi-faceted roles and diverse outcomes. Surv Ophthalmol 1997; 42: 71-82.
146. Oresmaa L, Kotikoski H, Haukka M, Oksala O, Pohjala E, Vapaatalo H, et al. Synthesis, occular effects, and nitric oxide donation of imidazole amidoximes. Europ J Med Chem 2006; 41: 1073-9.
147. Oresmaa L, Kotikoski H, Haukka M, Oksala O, Pohjala E, Vapaatalo H, et al. Synthesis and occular effects of imidazole nitrolic acid and amidoxime esters. Bioorg Med Chem Lett 2006; 16: 2144-7.
148. Fox KR, Sansom. CE, Stevens MPG. Footprinting studies on the sequence-selective binding of pentamidine to DNA. FEBS Lett 1990; 266: 150-4.
149. Edwards KJ, Jenkins TC, Neidle S. Crystal-structure of a pentamidine oligonucleotide complex - Implications for DNA-binding properties. Biochemistry 1992; 31: 7104-9.
150. Brown DG, Sanderson MR, Skelly JV, Jenkins TC, Brown T, Garman E. et al. Crystal-structare of a berenil dodecanucleotide complex - the role of water in sequence-specific ligand binding. EMBO J 1990; 9:1329-34.
151. Brown DG, Sanderson MR, Garman E, Neidle S. Crystal-structure of a berenil-D(CGCAAATTTGCG) complex - an example of a drug DNA recognition based on sequence-dependent structural features. J Mol Biol 1992, 226: 481-90.
152. Greenhill JV, Lue P. Amidines and guanidines in medicinal chemistry. Prog Med Chem 1993; 30: 203-326.
153. King H, Lourie E, Yorke W. Chemotherapy. XIX. Further report on new trypanocidal substances. Ann Trop Med Parasitol 1938; 32: 177-92.
154. Lourie EM, Yorke W. Studies in chemotherapy. XXI. The trypanocidal action of certain aromatic diamidines. Ann Trop Med 1939; 33: 289-304.
155. Wang MZ, Saulter JY, Usuki I, Cheung YL, Hall M, Bridges AS, et al. CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic pro-drug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab Dispos 2006; 34:1985-94.
156. Apted FIC. Present status of chemotherapy and chemoprohylaxis of human trypanosomiasis in the Eastern Hemisphere. Pharmacol Ther 1980; 11: 391-413.
157. Bryceson ADM, Chulay JD, Mugambi M, Were JB, Gachihi G, Chunge CN, et al, Visceral leishmaniasis unresponsive to antimonial drugs II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans Roy Soc Trop Med Hyg 1985; 79: 705-14.
158. Hughes WT, McNabb PC, Makres TD, Feldman S. Efficacy of trimethoprim and sulfamethoxazole in prevention and treatment of pneumocystis-carinii pneumonitis. Antimicrob Agents Chemother 1974; 5: 289-93.
159. Berger BJ, Reddy VV, Le ST, Lombardy RJ, Hall JF, Tidwell RR. Hydroxylation of pentamidine by rat-liver microsomes. J Pharmacol Exp Ther 1991; 256: 883-9.
160. Clement B, Raether W. Amidoximes of pentamidine: Synthesis, trypanocidal and leishimaniacidal activity. Arzneim-Forsch 1995; 35: 1009-14.
161. Clement B. Benzamidoxime derivatives for treatment of protozoal infections. Ger. Offen DE 4321444; Chem Abstrs 1995; 122: 151361g.
162. Lamb ID, White AC. Some amidines and amidoximes with trypanocidal activity. J Chem Soc 1939; 1253-7.
163. Andrewes CH, King H, Walker J. Experimental chemotherapy of typhus. Anti-rickettsial action of p-sulphonamidobenzamidine and related compounds. Proc R Soc Lond Ser B 1946; 133: 20-62.
164. Buu-Hoi NP, Welsch M, Xuong ND, Thang KV. A new group of tuberculostatic compounds, the amidoximes. Experientia 1954; 10: 169.
165. Chabrier P, Maillard G, Quevauviller A. Nouvelles recherches sur les rapports entre structure chimique, activite antibacterienne, antifungique et toxicite, dans la serie des esters de l'acide dithiocarbamique Ndisubstitue. Ann Pharm Fr 1956; 14: 720-8.
166. Fuller AT, Tonkin IM, Walker J. Chemotherapeutic agents of the sulphone type. II. Sulphones related to benzamidine and benzylamine. J Chem Soc 1945; 633-7.
167. Boykin DW. Antimicrobial Activity of the DNA Minor Groove Binders Furamidine and Analogues. J Braz Chem Soc 2002; 13: 763-71.
168. Hall JE, Kerrigan JE, Ramachandran K, Bender BC, Stanko JP, Jones SK, et al. Anti-Pneumonocystis Activities of Aromatic Diamidoxime Prodrugs. Antimicrob Agents Chemother 1998; 42: 666-74.
169. Jones SK, Hall JE, Allen MA, Morrison SD, Ohemeng KA, Reddy VV, et al. Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1990; 34: 1026-30.
170. Tidwell RR, Bell CA. Pentamidine and related compounds in the treatment of Pneumocystis carinii infection. In: Watzer P Ed, Pneumocystis carinii, 2nd ed. Marcel Dekker, New York, N.Y. 1993, pp. 561-83.
171. Tidwell RR, Jones SK, Naiman NA, Berger LC, Brake WB, Dykstra CC, et al. Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1993; 37: 1713-6.
172. Das BP, Boykin DW. Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J Med Chem 1977; 20: 531-6.
173. Steck EA, Kinnamon KE, Davidson DE, Duxbury RE, Johnson AJ, Masters RE. Trypanosoma-rhodesiense - evaluation of the antitrypanosomal action of 2,5-bis(4-guanylphenyl)furan dihydrochloride. Exp Parasitol 1982; 3: 133-44.
174. Blagburn BL, Drain KL, Land TM, Moore PH, Lindsay DS, Kumar A, et al. Dicationic furans inhibit development of Cryptosporidium parvum in HSD/ICR suckling Swiss mice. J Parasitol 1999; 84: 851-6.
175. Boykin DW, Kumar A, Spychala J, Zhou M, Lombardy RJ, Wilson WD, et al. Dicationic diarylfurans as anti-pneumocystis carinii agents. J Med Chem 1995; 38: 912-6.
176. Kumar A, Stephens CE, Boykin DW. Palladium catalyzed cross-coupling reactions for the synthesis of 2,5-disubstituted furans. Heterocycl Comm 1999; 5: 301-4.
177. Boykin DW, Kumar A, Hall JE, Bender BC, Tidwell R.R. Antipneumonocystis activity of bis-amidoximes and bis-O-alkylamidoximes prodrugs. Bioorg Med Chem Lett 1996; 6: 3017-20.
178. Ansede JH, Anbazhagan M, Brun R, Easterbrook JD, Hall JE, Boykin DW. O-Alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of trypanosoma brucei rhodesiense infection. J Med Chem 2004; 47: 4335-9.
179. Zhou L, Lee K, Thakker DR, Boykin DW, Tidwell RR, Hall JE. Enhanced permeability of the antimicrobial agent 2,5-bis(4-amidinophenyl)furan across Caco-2 cell monolayers via its methylamidoxime prodrug. Pharm Res 2002; 19: 1689-95.
180. Stephens CE, Patrick DA, Chen H, Tidwell RR, Boykin DW. Synthesis of deuterium-labelled. 2,5-Bis(4-amidinophenyl)furan, 2,5-Bis[4-(methoxyamidino) phenyl]furan, and 2,7-diamidinocarbazole. J Label Compd Radiopharm. 2001; 44: 197-208.
181. Tidwell RR, Boykin DW. In: Demeunynck M, Bailly C, Wilson WD Eds, Dicationic DNA minor groove binders as antimicrobial agents. In small molecule DNA and RNA binders: From synthesis to nucleic acid complexes. Wiley-VCH: New York 2003; Vol. 2, pp. 414-60.
182. Ismail MA, Brun R, Easterbrook JD, Tanious FA, Wilson WD, Boykin DW. Synthesis and antiprotozoal activity of aza-analogues of furamidine. J Med Chem 2003; 46: 4761-9.
183. Mazur S, Tanious F, Ding D, Kumar A, Boykin DW, Neidle S, et al. Large hydrophobic contributions are involved in DNA minor-groove complex formation with a series of diphenylfuran dications: Surface plasmon resonance and isothermal titration calorimetry studies. J Mol Biol 2000; 300: 321-37.
184. Boykin DW, Kumar A, Xiao G, Wilson WD, Bender BC, McCurdy DR, et al. 2,5-bis[4-(N-alkylamidino)phenyl]furans as anti-Pneumocystis carinii agents. J Med Chem 1998; 41: 124-9.
185. Matile H, Pink JRL. Plasmodium falciparum malaria parasite cultures and their use in immunology. In: Lefkovits I, Pernis B. Eds, Immunological Methods; Academic Press: San Diego 1990; pp. 221-34.
186. Ismail MA, Boykin DW. Synthesis of deuterium-labelled 6-[5-(4-amidinophenyl) furan-2-yl]nicotinamidine and N-alkoxy-6-{5-[4-(N-alkoxyamidino) phenyl]-furan-2-yl}-nicotinamidines. J Label Compd Radiopharm 2004; 47: 233-42.
187. Ismail MA, Brun R, Wenzler T, Tanious FA, Wilson WD, Boykin DW. Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo [1,2-apyridines as antiprotozoal agents. J Med Chem 2004; 47: 3658-64.
188. Hamdouchi C, Blas J, Prado M, Gruber J, Heinz BA, Vance L. 2- Amino-3-substituted-6-[(E)-1-phenyl-2-(N- methylcarbamoyl)vinyl]imidazo[1,2-a]pyridines as a novel class of inhibitors of human rhinovirus: Stereospecific synthesis and antiviral activity. J Med Chem 1999; 42: 50-9.
189. Hamama WS, Zoorob HH. Chemistry of bicyclic pyridines containing a ring-junction nitrogen. Tetrahedron 2002; 58: 6143-62.
190. Sundberg RJ, Biswas S, Murthi KK, Rowe D. Bis-cationic heteroaromatics as macrofilaricides: Synthesis of bis-amidine and bis-guanylhydrazone derivatives of substituted imidazo-[1,2-a]pyridines. J Med Chem 1998; 41: 4317-28.
191. Chackal-Catoen S, Miao Y, Wilson WD, Tanja Wenzier T, Brunb R, Boykin DW. Dicationic DNA-targeted antiprotozoal agents: Naphthalene replacement of benzimidazole. Bioorg Med Chem 2006; 15: 7434-45.
192. Ismail MA, Arafa RK, Brun R, Wenzler T, Miao Y, Wilson WD, et al. Synthesis, DNA affinity, and antiprotozoal activity of linear dicationios: Terphenyl diamidines and analogues. J Med Chem 2006; 49: 5324-32.
193. Wang S, Hall JE, Tanious FA, Wilson WD, Patrick DA, McCurdy DR, et al. Dicationic dibenzofuran as anti-Pneumocystis carinii pneumonia agents: Synthesis, DNA binding, and anti-P.carinii activity in an immunosuppressed rat model. Eur J Med Chem 1999; 34: 215-24.
194. Patrick DA, Hall JE, Bender BC, McCurdy DR, Wilson WD, Tanious FA, et al. Synthesis and anti-Pneumocystis carinii pneumonia activity of the novel dicationic dibenzothiophenes and orally active prodrugs. Eur J Med Chem 1999; 34: 575-83.
195. Patrick DA, Boykin DW, Wilson WD, Tanious FA, Spyhala J, Bender BC, et al. Anti-Pneumocystic carinii pneumonia activity of dicationic carbazoles. Eur J Med Clem 1997; 32: 781-93.
196. Sygusch J, Beaudry D, Allaire M. Molecular architecture of rabbit skeletal-muscle aldolase at 2.7 - a resolution. Proc Natl Acad Sci USA 1987; 84: 7846-50.
197. Hall DR, Leonard GA, Reed CD, Watt CI, Berry A, Hunter WN. The crystal structure of Escherichia coli class II fructose-1,6- bisphosphate aldolase in complex with phosphoglycolohydroxamate reveals details of mechanism and specificity. J Mol Biol 1999; 287: 383-94.
198. Singer M, Rossmiesse P, Cali BM, Liebke H, Gross CA. The Escherichia coli ts8 mutation is an allele of fda, the gene encoding fructose-1,6-diphosphate aldolase. J Bacteriol 1991; 173: 6242-8.
199. Böck A, Neidhart FC. Properties of a mutant of Escherichia coli with a temperature-sensitive fructose-1,6-diphosphate aldolase. J Bacteriol 1966; 92: 470-6.
200. Fonvielle M, Weber P, Dabkowska K, Therisod M. New highly selective inhibitors of class II fructose-1,6-bisphosphate aldolases. Bioorg Med Chem Lett 2004; 14: 2923-6.
201. Kabay N, Hayashi T, Jyo A, Egawa HJ. Amidoxime resins based on poly(acrylonitrile-co-vinilidene chloride-co-divinylbenzene) and their behavior in uptake of uranium from sea water. J Appl Polym Sci 1994; 54: 333-8.
202. Lin W, Lu Y, Zeng H. Extraction of gold from Au(III) ion containing solution by a reactive fiber J Appl Polym Sci 1993; 49: 1635-8.
203. Saliba R, Gauthier R, Petit-Ramel M. Adsorption of copper(II) and chromium(III) ions onto amidoximated cellulose. J Appl Polym Sci 2000; 75: 1624-31.
204. Shukla SR, Sakhardande VD. Column studies on metal-ion removal by dyed cellulosic materials. J Appl Polym Sci 1992; 44: 903-10.
205. Ali AAM, El-Sawy NM, Al Sagheer FA. Radiation polymerization of 4-N-Acryloylamidobenzonitrile: Amidoximation, complexation and biological activity. Intern J Polymer Mater 2005; 54: 359-73.
206. El-Sawy NM, Al Sagheer FA. Radiation-induced graft polymerization of acrylic acid onto poly(tetrafluoroethylene-perfluorovinyl ether) copolymer films: Complexation with some transition metals and biological activity. Eur Polym J 2001; 37: 161-6.
207. Park JS, Kim JH, Nho YC, Kwon OH. Antibacterial activities of acrylic acid-grafted polypropylene fabric and its metallic salt. J Appl Polym Sci 1998; 69: 2213-20.
208. Buo-Hoï N, Lecocq J. New derivatives of p-mercaptobenzoic acid. Bull Chem Soc France 1946; 13: 139-47.
209. Eloy F, Mirocha CJ. 5-nitro-2-furylamidoximes. US 1347874; Chem Abstr 1968; 68: 87139c.
210. Von Esch AM, Crovetti AJ. 5-nitro-2-furoylamidoximes. US 3272828; Chem Abstr 1966; 65: 18560c.
211. Von Esch AM, Crovetti AJ. Antibacterial and antifungal substituted 5-nitro-2-furylamidoximes. US 3660390; Chem Abstr 1972; 77: 61794y.
212. Saiwaka I, Wada T. β-(5-Nitro-2-furyl)acrylamide oxime. Japan 9334 (1967); Chem Abstr 1968; 68: 95663j.
213. Saiwaka I, Wada T. β-(5-Nitro-2-furylacrylamide oxime derivatives. Japan 9335 (1967); Chem Abstr 1968; 68: 95664k.
214. Norwich Pharmacal Co. N-(Methylcarbamyl)-5-nitrofuran-2-carboxamidoxime. Netherlands 6500124; Chem Abstr 1996; 64: 8135d.
215. Leandri G, Maioli L, Ruzzier L. Synthesis and antibacterial activity of aromatic amidoxime and diazafuran derivatives. Boll Sci Fac Chim Ind Bologna 1957; 15: 57-62; Chem Abstr 1958; 52: 7291.
216. Von Esch AM, Sherman WR. 5-nitro-2-furylamidoxime. US 3097214; Chem Abstr 1963; 59: 13950d
217. Treuner U, Breuer H. 5-Nitro-2-thiazolecarboxamide oxime derivatives. Ger. Offen 2225434; Chem Abstr 1973; 78: 84396e.
218. Crovetti A, Von Esch A, Thill R. Halomethyl-1,2,4-oxadiazoles. J Heterocycl Chem 1972; 9: 435-42.
219. Abele E, Abele R, Lukevics E. Pyridine Oximes: Synthesis, Reactions, and Biological Activity. Chem Heterocyclic Comp 2003; 39: 825-65.
220. Bernasek E. Notes - Pyridineamidoximes. J Org Chem 1957; 22: 1263.
221. Delaby R, Reynaud P, Tupin T. Pyridine amidines and amidoximes. Bull Soc Chim France 1957; 714-7.
222. Spasov A, Golovinskii E. Syntheses in the pyridine series. I. Nicotinic and isonicotinic acid nitriles and amidoximes. Compt Rend Acad Bulg Sci 1958; 11: 287-89; Chem Abstr 1959; 53: 18026.
223. Yoshitomi Pharmaceutical Industries, Ltd. Pyridinecarboxamide oximes. Jpn Tokkyo Koho JP 82 13542; Chem Abstr. 1982; 97: 182215g.
224. Poziomek EJ, Melvin AR. Aromatic glyoxylonitrile oximes. US 3209008; Chem Abstr 1965; 63: 18041g.
225. Majewski M, Serafin B, Faff J, Borkowska G. Potential acetylcholinesterase reactivators - pyridine oxime derivatives. 1. Eur J Med Chem - Chim Ther 1978; 13: 403-5.
226. Krivenchuk VE, Kokshareva NV, Sasinovich LM, Petrun'kin VE, Kagan YS. Thiohydroximic ethers. 2. pyridine-4-thiohydroxime S-diethylaminoethylate and its physiological activity. Khim-Farm Zh 1975; 9: 18-20.
227. Majewski M, Serafin B, Oklesinska T. Isolation and reactions of pyridine-3-nitrile oxide. Rocz Chem 1977; 51: 975-8.
228. Kocevar M, Perdih M, Petric A, Polanc S, Sollner M, Vercek B. Transformations starting from pyridinecarboxamide oximes. Vestn Slov Kem Drus 1990; 37: 373-82; Chem Abstr 1991; 114: 228687.
229. Golowinsky E, Markov KIZ. The action of nicotinic acid nitrites and amidoximes as growth factors for proteus vulgaris and Staphylococcus aureus. Naturforsch 1958; 13B: 725-6.
230. Nakanishi M, Tsuda Y. Pyridineamide oxime derivatives. Jpn Kokai 73 10075; Chem Abstr 1973; 78, 111133a.
231. Takacs K, Nagy PL, Kiss I, Simay A, Szentivanyi M, Virag S, Farago K. (3-amino-2-hydroxypropyl)-amidoxime derivatives. Ger Offen 2738589; Chem Abstr 1978; 89: 6123b.
232. Abele E, Abele R, Arsenyan P, Shestakova I, Kanepe I, Antonenko I, et al. Synthesis and cytotoxicity of silicon and germanium containing pyridine oxime O-ethers. Bioinorg Cbem Appl 2003; 1: 299-308.
233. Dagli DJ, Wu GS, Marcovac A, Lamontagne MP. Bis-(amidoximes) and bis-(amidines) as candidate antitrypanosomal agents. Abstr Pap Am Chem Soc 1989; 198: 31.
234. Chen BH, Jiao KF, Song HQ. Synthesis of dipyridinium mono-4-amidoxime iodides. Acta Chim Sin 1986; 44: 417-20.
235. Cristalli G, Frachetti P, Grifantini M, Ripa S. 2,2′-bipyridyl-6-carboxamidoximes with potential antitumor and antimicrobial properties. Pharmaco Ed Sci 1986; 41: 499-507.
236. Bandiera T, Marinone F, Albini E. Synthesis and antifungal activity of some allylamine derivatives. J Heterocycl Chem 1987; 24: 1597-8.
237. Khalilova S, Poplevskaya I, Blonskaya LI, Blagodarny YA. Thiosemicarbazones of N-arylacetylformamidoximes and their tuberculostatic properties. Khim-Farm Zh 1986; 26: 1469-72.
238. Flora K, van't Riet B, Wampler G. Antitumor activity of amidoximes (hydroxyurea analoques) in murine tumor systems. Cancer Res 1978; 38: 1291-5.
239. Rosenkranz HS, Hjiorth R, Carr HS. Studies with hydroxyurea: The biologic and metabolic properties of formamidoxime. Biochim Biophys Acta 1971; 232: 48-60.
240. Buu-Hoï N, Xuong W, Thang NV. Amidoximes of halogenated o- and p-hydroxybenzoic acids. Bull Soc Chim France 1954; 294-6.
241. Bukowski L, Janowier M. 1-Methyl-1H-2-imidazo[4,5-b]pyridine-carboxylic acid and some of ist derivatives with suspected antituberculotic activity. Pharmazie 1996; 51: 27-30.
242. Terada M, Ishih A, Tungtrongchitr A, Sano M, Shomura T. Effects of PF1022A on developing larvae of Angiostrongylus costariciensis in mice, with special reference to route, dose and formulation. Jpn J Parasitol 1993; 42: 199-210.
243. Kachi S, Terada M, Hashimoto H. H. Effects of amorphous and polymorphs of PF1022A, a new antinematode drug, on angiostrongylus costaricensis in mice. Jpn J Parasitol 1998; 77: 235-45.
244. Conder GA, Johnson SS, Nowakowski DS, Blake TE, Dutton FE, Nelson SJ, et al. Anthelmintic profile of the cyclodepsipeptide PF1022A in vitro and in in vivo models. J Antibiotics 1995; 48: 820-3
245. von Samson-Himmelstjerna G, Harder A, Schnieder T, Kalbe J, Mencke N. In vivo activities of the new anthelmintic depsipeptide PF1022A. Parasitol Res 2000; 86: 194-9.
246. Sasaki T, Takagi M, Yaguchi T, Miyadoh S, Okada T, Koyama M. A new anthelmintic cyclodepsipeptide, PF1022A, J Antibiotics 1992; 45: 692-7.
247. Ohyama M, Iinuma K, Isogai A, Suzuki A. Total synthesis of the anthelmintic cyclodepsipeptide, PF1022A. Biosci Biotech Biochem. 1994; 58: 1193-4.
248. Kobayashi M, Nanba T, Toyama T, Saito A. Synthesis and anthelmintic activity of the cyclodepsipeptide, PF1022A. Annu Rep Sankyo Res Lab 1994; 46: 67-75.
249. Dutton FE, Nelson SJ. Synthesis of PF1022A, an anthelmintic cyclodepsipeptide. J Antibiotics 1994; 47: 1322-7.
250. Saeger B, Schmitt-Wrede HP, Dehnhardt M, Benten WPM, Krucken J, Harder A, et al. Latrophilin-like receptor from the parasitic nematode Haemonchus contortus as target for the anthelmintic depsipeptide PF1022A. FASEB J 2001; 15: 1332-4.
251. Harder A, von Samson-Himmelstjerna G. Cyclooctadepsipeptides-a new class of anthelmintically active compounds Parasitol Res 2002; 88: 481-8.
252. Jeschke P, Harder A, von Samson-Himmelstjerna G, Etzel W, Gau W, Thielking G, Bonse G. Synthesis of anthelmintically active N-methylated amidoxime analogues of the cyclic octadepsipeptide PF1022A. Pest Manag Sci 2002; 58: 1205-15.
253. Rao VS, Sauve G, Lajoie G, Belleau B. The solution conformation of chemotactic peptides and their backbonemodified analogs. Nuclear magnetic resonance and computermodeling studies with active amidoxime analogs of formylmethionyl-leucyl-phenylalanine. Spectroscopy (Ottawa) 1995; 4: 153-70.
254. Jeschke P, Harder A, von Samson-Himmelstjerna G, Bonse G. Cyclo-imino depsipeptides and their utilization in controlling endoparasites (Bayer AG), PCT Application 0 076 985, 2000.
255. Martin RJ, Harder A, Londershausen M, Jeschke P. Anthelmintic actions of the cyclic depsipeptide PF1022A and its electrophysiological effects on muscle cells of Ascaris suum. Pestic Sci 1996; 48: 343-9.
256. Rapson EB, Jenkins DC, Chilwan AS. Improved detection of anthelmintic activity in an in vitro screen utilizing adult Nippostrongylus brasiliensis. Z Parasitenkd 1987; 73: 190-1.
257. Jeschke P, Harder A, Etzel W, Gau W, Thielking G, Bonse G, et al. Synthesis and anthelmintic activity of thioamide analogues of cyclic octadepsipeptides such as PF1022A. Pest Manag Sci 2001; 57: 1000-6.
258. Newman NF. N,N-Dimethylbenzamide oximes. Ger. Offen 2132598; Chem Abstr 1973; 76: 72275k.
259. Gutman AD. 2,6-Dichlorophenyl-substituted phenyl-nitroazones and their use as herbicides. US Patent 4425271, 1984.
260. Gutman AD. α-(Phenylazo)-2,6-dichlorobenzaldimino esters and their use as herbicides. US 4270947; Chem Abstr 1981; 95, 115055a.
261. Farge D, Leboul J, LeGoff Y, Poiget G. Amidoxime derivatives. Ger. Offen 2640484; Chem Abstr 1977; 87, 39141t.
262. Abele E, Lukevics E. Furan and thiophene oximes: Synthesis, reactions and biological activity. Chem Heterocycl Comp 2001; 37: 141-69.
263. Farge D, Leboul J, Le Goff Y, Poiget G. Thiophene carboxamidoxime derivatives and their use in phytohormonal and herbicidal compositions. Ger Offen 2831983; Chem Abstr 1979; 90: 181591v.
264. Philagro SA., Thiophene amidoxime derivatives, and phytohormonal and herbicidal compositions containing them. IL 55228; Chem Abstr 1995; 99: 175584q
265. Rheinheimer J, Rose I, Grote T, Lorenz G, Strathmann S. New pyridyl O,N-disubstituted amidoxime and pyridazinyl O,N-disubstituted amidoxime derivatives useful as plant fungicides and for control of fungal attack on materials, e.g. wood German Patent No 19837794 A1, 2000.
266. Benn FR, Charlton PT, Harmer GLM. Antihistaminic amino acetamidoximes. British Patent 895495; Chem Abstr 1962; 57: 13673b.
267. Sindelár K, Protiva M, Metisova J, Sedivy Z, Hrabantova M, Valchar M. Synthesis of (2-(phenylthio)phenyl)acetamidines and related amidoximes as potential antidepressants. Collect Czech Chem Comm 1988; 53: 381-8.
268. Larocca J, Gibson C N-Arylglyoxylohydroxamyl derivatives of nitrogen mustard. J Pharm Sci 1976; 56: 1683-4.
269. Poplavskaya IA, Abdullin KA. Symposium on the synthesis of pharmaceutically active compounds, Odessa, 1976; Abstracts p. 100.
270. Poplavskaya IA, Abdullin KA. Symposium on problems in experimental chemotherapy, Cernogolovka, 1980; Abstracts, p. 120.
271. Poplevskaya IA, Kurmangalieva RG, Khalilova. SF, Abdullin KA, Kudrina IK, Kabiev OK, Acetylformamidoxime derivatives and their antiblastic properties. Akad Nauk Kaz SSR. 1980; 52: 114-27; Chem Abstr 1981; 94: 174593b.
272. Poplavskaya IA, Kurmangaliyeva RG, Khalilova S, Abdullin KA, Kudrina IK. Derivatives of acetylformamide oxime and their cytostatic properties. Khim-Farm Zh 1981; 15: 16-21; Chem Abstr 1981; 95: 73413h.
273. Scotese A, Santilli A, Nelson G. Synthesis and antiarrhythmic activity of substituted (2-pyrimidinylthio)acetamidoximes. J Med Chem 1975; 18: 852-4.
274. Lafon L. 4-Phenoxy-3-hydroxybutyramidoxime derivatives, and their therapeutic use. Fr. Demande FR 2503147; Chem Abstr 1983; 98, 178973f.
275. Lafon L. Acetamidoxime derivatives. Belg. 866163; Chem Abstr 1979; 90, 103986p.
276. Fauran C, Bourgéry G, Gouret C. 2-(N-Phenylcarbamoyl)acetamide oximes. Ger. Offen 2607764; Chem Abstr 1977; 86, 5191y.
277. Najer H, Obitz D. Propionamidoxime derivatives. Fr. Demande FR 2422630; Chem Abstr 1980,,93: 7898c.
278. Menin J, Mangane M. Amidoxime derivatives and their therapeutic use.Fr. Demande FR 2485006; Chem Abstr 1982; 96, 199332v.
279. Cervená I, Hrubantová M, Bartosová M, Protiva M. Neurotropic and psychotropic agents. 169. Synthesis of arylthioacetamidoximes as potential anti-depressants. Collect Czech Chem Comm 1981; 46: 1188-98.
280. Protiva M, Cervená I. Hrunantova M, Bartosova M. Arylthio-acetamidoximes. Czech. CS 213038; Chem Abstr 1984; 101: 72455d.
281. Obitz D. Heterocyclic amidoximes, derivatives, and their therapeutic uses. Eur Pat Appl EP 67094; Chem Abstr 1983; 98: 179232a.
282. Najer H, Obitz D, Kaplan JP. Amidoxime derivatives and their use in therapy. Fr. Demande M 2506764; Chem Abstr 1983; 99: 38360z.
283. Poplavskaya, I, Karmangaliyeva R, Khalilova S, Zaks AS, Kapitonenko TA. Synthesis and study of psychotropic: Activity of arylace-ty1formamidoxime hydrazones. Khim-Farm Zh 1983; 290-4.
284. Abele E. Abele R, Dzenitis O, Lukevics E. Indole and isatin oxidimes: synthesis, reactions and biological activity. Chem Heterocycl Comp 2003; 39: 3-35.
285. Pelosi SS Jr. 5-Phenyl-2-furamidoximes. US 3946049; Chem Abstr 1976; 85: 21083z.
286. Andersen KF, Jorgensen AS, Bræmstrup C. Oxadiazoles as bioisosteric transformations of carboxylic functionalities. Part I. Eur J Med Chem 1994; 29: 393-9.
287. Mull RP, Schmidt P, Dapero MR, Higgins J, Weisbach MJ. Antihypertensively active amidoximes. J Am Chem Soc 1958; 80: 3769-72
288. Mull RP, Maxwell R, Plummer A. Antihypertensive activity of hexahydro-1-azepin-azepinepropionamidoxime. Nature 1957; 180: 1200-1.
289. Bell MR. Amidoximes, amidines, and guanidines for medical use. Belg. 659467; Chem Abstr 1966; 64: 2098h.
290. Henderson RM. Antihypertensive N-methylalkanamide oxime carbamates. Ger Offen 2318960; Chem Abstr 1974; 80: 27006v.
291. Bailey DM. 2-Alkoxy-2-(naphthyl)alkanamidoximes. US 3720714; Chem Abstr 1973; 78: 14767On.
292. Nishimura A, Shimizu M, Uno H, Hirooka T, Masuda Y, Kurokawa M. Pharmaceutical 1,2-benzisoxazoles. Ger. Offen 2313256; Chem Abstr 1973; 79: 137159j.
293. Nishimura A, Shimizu M, Uno H, Hirooka T, Masuda Y, Kurokawa M. Amidoximes. Japan Kokai 74 116056; Chem Abstr 1975; 83: 10038w.
294. Nishimura A, Shimizu M, Uno H, Hirooka T, Masuda Y, Kurokawa M. Acylamidoximes. Japan Kokai 74 116057; Chem Abstr 1975; 83: 10039x.
295. Nishimura A, Shimizu M, Uno H, Hirooka T, Masuda Y, Kurokawa M. 1,2-benzisoxazole-3-acetamidoximes. Japan Kokai 75 52055; Chem Abstr 1975; 83: 193285s.
296. Nishimura A, Shimizu M, Uno H, Hirooka T. Masuda Y, Kurokawa M. Amidoximes. Japan Kokai 75 50371; Chem Abstr 1975; 83: 206232z.
297. Nishimura A, Shimizu M, Uno H, Hirooka T, Masuda, Y, Kurokawa M. Amidoxime derivatives. Japan Kokai 75 50369; Chem Abstr 1975; 83: 206233a.
298. Uno H, Natsuka K, Kurokawa M, Shimizu M, Hatano N, Karasawa T. 1,2-Benzisoxazole-3-acetamidoximes. Japan Kokai 75 52057; Chem Abstr 1975; 83: 193287u.
299. Nishimura A, Shimizu M, Uno H, Hirooka T, Masuda Y, Kurokawa M. 5-Fluoro-1,2-benzisoxazole-3-acetamidoxime. Japan Kokai 75 29554; Chem Abstr 1975; 83: 97266r.
300. Nishimura A, Shimizu M, Uno H, Hirooka T, Masuda Y, Kurokawa M. 5-Fluoro-1,2-Benzisoxazole-3-acetamidoxime. Japan Kokai 75 29555; Chem Abstr 1975; 83: 131574b.
301. Areschka A, Descamps M. Benzofuran-derived amidoximes and process for preparing the same. Brit. 1508210; Chem Abstr 1978; 89: 163390d.
302. Areschka A, Makauh J, Verbruggen F, Houben C, Descamps M, Heyndrickx JP, et al. Benzofurans. 61. Potential antihypertensive 3-benzo-furanylacetamidoximes. Eur J Med Chem 1977; 12; 37-91.
303. Ray SM, Lahiri SC. Investigation on synthesis, hypotensive activity and highly selective adrenergic antagonistic activity of some simple and substituted indane derivatives. J Indian Chem Soc 1991; 68: 549-55.
304. Nicolaides D, Fylaktakidou KC, Litinas KE, Hadjipavlou-Litina D. Synthesis and biological evaluation of several coumarin-4-carboxamidoxime and 3-(coumarin-4-yl)-1,2,4-oxadiazole derivatives. Eur J Med Chem 1998; 33: 715-24.
305. Tandon M, Tandon P, Barthwhal JP, Bhalla TN, Bhagrava KP. Anti-inflammatory and Anti-proteolytic activities of newer indolyl isoquinolines. Arzneim Forsch Drug Res 1982, 32: 1233-5.
306. Riffaud JP, Dupont C, Rene L, Royer R. Analgesic and antiinflammatory prorerties of 2-benzofuran amidoximes. Eur J Med Chem-Chim Ther 1982; 17: 577-81.
307. Somasekhara S, Upadhyaya NV. β-Triazolinonylpropionamidoximes and their derivatives. J Ind Chem Soc 1972; 49: 201-2.
308. Wei PHL, Bell SC. Antiviral thiazolo [5,4-b] pyridine compounds. US 4443606; Chem Abstr 1984; 101: 23468b.
309. Ganem B. Inhibitors of carbohydrate-processing enzymes: Design and synthesis of sugar-shaped heterocycles. Acc Chem Res 1996; 29: 340-7
310. Oszczapowicz J, Orlinski R, Walczynska H. Amidines. 4. structure- basicity relation in monosubstituted N,N-(alkylene-alpha, omega)-N'-phenylformamidines. Pol J Chem 1979; 53: 2531-7.
311. El Ashry ESH, Rashed N, Shobier AHS. Glycosidase inhibitors and their chemotherapeutic value, part 3. Pharmazie 2000; 55: 403-15.
312. Papandreou G, Tong MK, Ganem B. Amidine, amidrazone, and amidoxime derivatives of monosaccharide aldonolactams: Synthesis and evaluation as glyosidase inhibitors. J Am Chem Soc 1993; 115: 11682-90.
313. Ganem B, Papandreou G. Mimicking the glucosidase transition state: Shape/ charge considerations. J Am Chem Soc 1991; 113: 8984-5.
314. Tong MK, Papandreou G, Ganem B. Potent, broad-spectrum inhibition of glycosidases by an amidine derivative of D-glucose. J Am Chem Soc 1990; 112: 6137-9.
315. Abe I, Rohmer M, Prestwich GD. Enzymatic cyclization of squalene and oxidosqualene to sterols and triterpenes. Chem Rev 1993; 93: 2189-206
316. Abe I, Prestwich GD. In: Barton DHR, Nakanishi K Eds, Comprehensive natural products chemistry 1998; Vol. 2.
317. Ourisson G, Rohmer M, Poralla K. Prokaryotic hopanoids and other polyterpenoid sterol surrogates. Annu Rev Microbiol 1987; 41: 301-33
318. Ganem B, Dong Y, Feng Zheng Y, Prestwich G. D. Amidrazone and amidoxime inhibitors of squalene hopene cyclase. J Org Chem 1999; 64: 5441-6.
319. Saji H, Horiuchi KS, Mukai T. Drud design of radioactive metal complexes for nuclear medical diagnosis. Biomed Res Trace Elements 2001; 12: 141-51.
320. 99mTc radiopharmaceuticals. Ann Nucl Med 2002; 16: 79-93.
321. 99mTc radiopharmaceuticals (I). Nucl Med Commun 1992; 13: 445-9.
322. 99mTc complexes of hydroxamamide derivatives. Appl Radiat Isot 1994; 45: 735-40.
323. 99mTc-hydroxamamides. Appl Radiat Isot 1997; 48: 571-7.
324. Pearce GA Jr, Pflaum RT. Internal of metal ion with amidoximes. J Am Chem Soc 1959; 81: 6505-8.
325. Nakayama M, Ono M, Haratake M. A new hydroxamamide-based ligand system for 99mTc labeling of proteins and polypeptides. Biomed Res Trace Elements 2003; 14: 29-33.
326. Xu H, Chu T, Wang X, Liu X. Facile synthesis of bis(hydroxamamide)-based tetradentate ligands for 99mTc-radiopharmaceutical. Appl Radiat Isot 2005; 62: 919-22.
327. 99mTc radiopharmaceuticals. Nucl Med Biol 1998; 25: 295-303.
328. 99mTc labeling of polypeptides. Bioconjugate Chem 1999; 10: 9-17.
329. Chu TW, Hu SW, Wei B, Wang Y, Liu XQ, Wang XY. Synthesis and biological results of the technetium-99m-labeled 4-nitroimidazole for imaging tumor hypoxia. Bioorg Med Chem Lett 2004; 14: 747-9.
330. Chu TW, Li RJ, Hu SW, Liu XQ, Wang XY. Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)-propanhydroxy-iminoamide (N2IPA) as a tumor hypoxia marker. Nucl Med Biol 2004; 31: 199-203.
331. Devel L, Vidal-Cros A, Thellend A. Synthesis of N-acetylxylos-amidoxime, a potensial transition state analog inhibitor of glycosyl-transferase. Tetrahedron Lett 2000; 41: 299-301
332. Garner P, Park JM. The synthesis and configurational stability of differentially protected beta-hydroxy-alpha.-amino aldehydes. J Org Chem 1987; 52:2361-4.
333. Uhlmann E, Peyman A. Antisense oligonucleotides: A new therapeutic principle. Chem Rev 1990; 90: 543-84.
334. Sanghvi YS, Cook PD. In: Chu CK, Baker DC Eds, Nucleosides and nucleotides as antitumor and antiviral agents; Plenum Press: New York, 1993; pp. 311-24.
335. Uhlmann E. In: Krohn K, Kirst HA, Maag H Eds, Antibiotics and antiviral compounds: Chemical synthesis and modification; VCH: Weinheim 1993; pp. 463-70.
336. Sanghvi YS. In: Chapleur Y Ed,CCarbohydrate mimics: concepts and methods; Wiley-VCH: Weinheim. 1998; pp. 523-36.
337. Herdewijn P. In: Chapleur Y EdC Carbohydrate mimics: concepts and methods; Wiley-VCH: Weinheim 1998; pp. 553-79.
338. Temsamani J, Agrawal S. In: De Clercq E Ed, Advances in antiviral drug design; JAI PrePs: London 1996; Vol. 2: pp. 1-39.
339. De Mesmaeker A, Häner R, Martin P, Moser HE. Antisense oligonucleotides. Acc Chem Res 1995; 28: 366-74.
340. Jung PMJ, Beaudegnies R, De Mesmaeker A, Wendeborn S. New and efficient synthesis of 5′-amino-5′-(S)-methyl-2′,5′- dideoxy-nucleosides. Tetrahedron Lett 2003; 44: 293-7 and references cited therein.
341. Blaskó A, Dempcy RO, Minyat EE, Bruice TC. Association of short-strand DNA oligomers with guanidinium-linked nucleosides. A kinetic and thermodynamic study. J Am Chem Soc 1996; 118: 7892-9.
342. 2). A kinetic and thermodynamic study. Biochemistry 1997; 36:7821-31.
343. Luo J, Bruice TC. Nanosecond molecular dynamics of hybrid triplex and duplex of polycation deoxyribonucleic guanidine strands with a complimentary DNA strand. J Am Chem Soc 1998; 120: 1115-23.
344. Linkletter BA, Szabo IE, Bruice TC. Solid-phase synthesis of deoxynucleic guanidine (DNG) oligomers and melting point and circular dichroism analysis of binding fidelity of octameric thymidyl oligomers with DNA oligomers. J Am Chem Soc 1999; 121: 3888-96.
345. Kojima N, Bruice TC. Replacement of the phosphorodiester linkages of RNA with guanidinium linkages: the solid-phase synthesis of ribonucleic guanidine. Org Lett 2000; 2: 81-4.
346. Kojima N, Szabo IE, Bruice T. C. Synthesis of ribonucleic guanidine: replacement of the negative phosphodiester linkages of RNA with positive guanidinium linkages. Tetrahedron 2002; 58: 867-9.
347. Gallos JK, Dellios CC. Synthegis of dinucleotides containing nitrone, hydroxylamine and amidoxime linkages. Tetrahedron Lett 2003; 44:5679-81.
348. Mohan V, Griffey RH, Davis DR. Structure and dynamics of MMI linked nucleotides. Tetrahedron 1995; 51: 6855-8.
349. Bailey DM. 2-Alkoxy-2-phenylalkane amidoximes. US 3607941; Chem Abstr 1971; 75, 129556p.
350. Treuner UD. (Arylsulfonyl)formamidoximes. Ger Offen 2248941; Chem Abstr 1973; 79, 18435m.
351. Yoshitomi Pharmaceutical Industries Ltd. Pyridinecarboxamide oximes. Jpn. Tokkyo Koho JP 82 13542; Chem Abstr 1982; 97: 182215g.
352. Glozman O, Orlove E, Voronina T. Synthesis and pharmacologic activity of amidoximes of (2-oxopirrolidino)alkane acids and relevant O-acyl derivatives. Khim-Farin Zh 1989; 23: 1147-52.
353. Hirata Y, Yanagisawa I, Ishii Y, Takeda. M. Guanidinothiazole compounds. Ger. Offen 3008056; Chem Abstr 1981; 94: 139794w.
354. Sauvé G, Rao V, Lajoie G, Belleau B. Backbone-modified oligopeptidic bioregulators - The synthesis and configuration of thiomide, amidoxime, cyanoamidine and amidrazone analogues of the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (F-MET-LEU-PHE-OR). Canad J Chem 1985; 63: 3089-101.
355. Vadon S, Custot J, Bouche JI, Mansuy D. Synthesis and effects on arginase and nitric oxide synthase of two novel analogs of N ω-hydroxyarginine, Nω-hydroxyindospicine and p-hydroxyamidino-phenylalanine. J Chem Soc Perkin Trans 1966; 645-8.
356. d'Amico JJ, Marvel JT. Imidamides derived from 2-oxo-3-benzothiazoline acetic acid, and their use as plant growth regulants. Eur Pat Appl 24889; Chem Abstr 1981; 95: 115525d.
357. Hiller H, Fischer A. Alkylaminooxanil oximes. US Patent 3766270, 1973.
358. Sinharay A, Bonin W. substituted N-phenylformamidoxime. Ger Offen 2717437; Chem Abstr 1979; 90:54644q.
359. Hodakowski LE, Bushey DF. Phosphorus esters of amidoximes, and compositions for and methods of controlling insects using them. US 4479946; Chem Abstr 1985; 102: 57850f.
360. Mitsui Toatsu Chemicals, Inc. Aryloxyphenoxypropionamide oximes. Jpn Kokai Tokkyo Koho JP 57169455; Chem Abstr 1983 ; 98: 107168m.